Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HuMax-IL8 in Advanced Solid Tumors
NCT02536469Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Aug 2015
- Primary completion
- Nov 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of adakitug in solid tumor, sponsored by Bristol Myers Squibb. Primary endpoint: Dose Limiting Toxicity at 28 days. Started Aug 2015; status: completed.
02
Drugs
adakitug
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02536469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02536469.